Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.

Kashiwagi, Tomoko; Okada, Yukiko; Nomoto, Ken

Kashiwagi, Tomoko; Okada, Yukiko; Nomoto, Ken.

Afiliação

Kashiwagi T; AbbVie GK, Mita 3-5-27, Minato-ku, Tokyo, 108-6302, Japan.
Okada Y; AbbVie GK, Mita 3-5-27, Minato-ku, Tokyo, 108-6302, Japan.
Nomoto K; AbbVie GK, Mita 3-5-27, Minato-ku, Tokyo, 108-6302, Japan. ken.nomoto@abbvie.com.

Paediatr Drugs ; 20(3): 291, 2018 06.

Article em En | MEDLINE | ID: mdl-29637469

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830058
https://dx.doi.org/10.1007/s40272-018-0291-3

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830058
https://dx.doi.org/10.1007/s40272-018-0291-3

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article